Repligen CORP

Repligen Corporation announced robust second quarter 2026 financial results, with revenue up 12% year-over-year, and raised its full-year financial guidance.

Repligen Corporation announced its definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion, aiming to expand its cell therapy capabilities.

Repligen Corporation announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals were approved.

Repligen Corporation announced robust first-quarter 2026 financial results, with a 15% year-over-year revenue increase and raised full-year adjusted EPS guidance.

Repligen Corporation reported strong fourth quarter and full year 2025 financial results, surpassing guidance, and provided optimistic 2026 financial projections with expected margin expansion.

Repligen Corporation announced the election of Dr. Martin D. Madaus as Chair of the Board, succeeding Tony J. Hunt upon his previously announced retirement.

Repligen Corporation reported a 14.8% increase in total revenue for the first quarter of 2026, reaching $194.3 million, driven by strong product sales across its bioprocessing technologies.

Repligen Corporation announced a significant increase in product revenue and a return to profitability for the third quarter and first nine months of 2025, driven by acquisitions and broad portfolio growth.

Repligen Corporation reported a significant increase in second-quarter revenue and net income, driven by strong performance in its Chromatography and Analytics franchises and recent acquisitions.

Repligen Corporation reports a 10.4% increase in total revenue for Q1 2025, driven by product revenue growth and recent acquisitions.

Repligen Corporation's Q3 2024 results show a revenue increase, but the company restated prior periods due to a material accounting error related to revenue recognition.

Repligen Corporation has filed an amended quarterly report to restate its financials for the three and six months ended June 30, 2024, due to a misapplication of accounting principles related to revenue recognition and has identified material weaknesses in internal controls.

Repligen Corporation announced a 16.4% increase in product revenue for 2025, reaching $737.96 million, alongside the remediation of a material weakness in revenue recognition but ongoing challenges with IT general controls and inventory valuation.

Repligen's 2024 10-K filing reveals stagnant revenue growth, offset by increased filtration product revenue, and identifies material weaknesses in internal control over financial reporting.

Repligen Corporation files an amended 10-K report restating its 2023 financials due to a misapplication of accounting principles related to revenue recognition and identifies material weaknesses in internal controls.

Repligen Corporation's 10-K filing outlines its business strategy, product portfolio, financial performance, and risk factors for the fiscal year ended December 31, 2023.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a combination of cash and Repligen common stock, aiming to accelerate growth in the cell therapy market.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion in a cash and stock deal.

Jason K Garland, CFO of Repligen Corp, sold 530 shares of common stock on July 16, 2026 for $150.00 per share.

Repligen Corporation's CFO, Jason K. Garland, has sold shares of common stock as part of a pre-arranged trading plan.

Repligen Corporation Director Martin D. Madaus acquired 995 restricted stock units and was granted a stock option, as detailed in a Form 4 filing.

Konstantin Konstantinov, a Director at Repligen Corp, was awarded 995 restricted stock units on May 14, 2026.

Repligen Corporation has released its 2026 Proxy Statement detailing the upcoming Annual Meeting, director elections, and executive compensation.

Repligen Corporation announces its 2025 Annual Meeting of Stockholders and provides details on voting for key proposals.

Repligen Corporation releases its 2025 proxy statement, outlining key proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation, and a liability amendment.

Repligen issues a supplement to its proxy statement clarifying that certain executive equity awards are subject to double-trigger, not single-trigger, acceleration upon a change in control.

Repligen Corporation's upcoming annual meeting on May 16, 2024, will include voting on the election of directors, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation.

Repligen Corporation's proxy statement details the agenda for the 2024 annual shareholder meeting, director nominees, executive compensation, and corporate governance highlights.

Vanguard Capital Management has reported beneficial ownership of 5% of Repligen Corp's common stock as of June 30, 2026.

The Vanguard Group filed an amended Schedule 13G for Repligen Corp, reporting zero beneficial ownership following an internal realignment.

The Roy T. Eddleman Living Trust and associated charitable trusts have reduced their aggregate beneficial ownership in Repligen Corporation to 4.86% of common stock.

T. Rowe Price Associates, Inc. has disclosed a 6.1% beneficial ownership stake in Repligen Corp. common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reaffirming its beneficial ownership of 9.3% of Repligen Corporation's common stock as of March 31, 2025.

T. Rowe Price Associates, Inc. has reported a 12.7% beneficial ownership stake in Repligen Corp, holding over 7.1 million shares as of December 31, 2024.